Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …”

Role of MIB2 and CAMK2 in FAT1-depndent regulation of YAP/TAZ protein levels and YAP/TAZ nuclear localization. by Rui Li (4631)

A proposed model for citrus tristeza virus (CTV) p20-mediated RNA silencing suppression. by Yongle Zhang (11355546)

Results of longitudinal analysis of mental health in HCWs. by A. H. Ayesha Lavell (16734002)

Characteristics of households participating in the SchistoBreak study in Pemba, Tanzania. by Lydia Trippler (10136316)

Spatial patterns of nodal module overlap (i.e., nodal entropy) for different network analysis strategies and their relationships with the main results. by Tianyuan Lei (19683861)

Patients’ demographics and clinical parameters. by Zi-Rong Chen (9227618)

“…Univariate GEE showed that a larger AL elongation in the initial 4 months was significantly associated with AL changes at 6 months (β = 0.354, <i><i>P</i></i> = 0.020, 6 ~ 12 months period from baseline) and 12 months (β = 0.560, <i><i>P</i></i> = 0.045, 6 ~ 18 months period from baseline) after that period in all myopic eyes.…”

Inhibition of ferroptosis alleviated the expression of hepatic by Haoyang Zhang (1706815)

Mean scores and 95% CI of mental health symptoms, COVID-19 admissions and effect size during follow-up. by A. H. Ayesha Lavell (16734002)

(A) Mobility rate, (B) Explored areas, (5C) Immobility time, (D) Frozen events for hole board test. by Hammad Ismail (4227988)

The performance of eigenvectors of the covariance matrix in a model with more complex population structure. by Joshua G. Schraiber (8027060)

Fig 4 - by Marjo K. Hytönen (8522271)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Baseline characteristics of cases and controls. by Soo Min Ahn (10333246)

“…Current exposure to sulfasalazine (aOR: 0.79, 95% CI: 0.65–0.97) and hydroxychloroquine (aOR: 0.83, 95% CI: 0.72–0.96) was associated with a decreased risk of stroke, while current exposure to glucocorticoids (aOR: 1.71, 95% CI: 1.46–2.00) and tocilizumab (aOR: 3.47, 95% CI: 1.70–7.08) was related to an increased risk of stroke.…”

Label-Free Quantitative Proteomic Analysis Reveals the Effects of Biogenic Silver Nanoparticles on Fusarium keratoplasticum and Their Therapeutic Potential in Galleria mellonella L... by Glaucia Rigotto-Caruso (22057974)

“…This study evaluated the antifungal activity and molecular effects of biogenic silver nanoparticles (AgNPs) synthesized using the culture filtrate of Epicoccum nigrum against Fusarium keratoplasticum, a highly resistant fungal species. AgNPs exhibited strong antifungal activity, with a MIC₅₀ of 1.79 μg/mL and 92.85% growth inhibition at 5.92 μg/mL. …”